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ABSTRACT
The combination of radiotherapy and pharmacological inhibition of cellular 
signal transduction pathways offers promising strategies for enhanced cancer cell 
inactivation. However, the molecular effects of kinase inhibitors especially on DNA 
damage detection and repair after X-irradiation have to be understood to facilitate the 
development of efficient and personalized treatment regimens. Therefore, we applied 
differential proteomics for analyzing inhibitor-induced changes in either chromatin-
bound or phosphorylated nuclear proteins. The effect of the multi kinase inhibitor 
sorafenib on DNA repair, chromatin binding and phosphorylation of nuclear proteins 
was analyzed in UT-SCC 42B head and neck cancer cells using metabolic labeling 
based differential proteomics (SILAC). Sorafenib significantly inhibited DNA repair 
but failed to significantly affect chromatin interactions of 90 quantified proteins. 
In contrast, analyzing nuclear phospho-proteins following sorafenib treatment, we 
detected quantitative changes in 9 out of 59 proteins, including DNA-repair proteins. 
In conclusion, the analysis of nuclear phospho-proteins by differential proteomics 
is an effective tool for determining the molecular effects of kinase inhibitors on 
X-irradiated cells. Analyzing chromatin binding might be less promising.
INTRODUCTION
To improve cancer treatment radiotherapy 
is combined with radiation response modifiers 
(radiosensitizers). In this context numerous kinase 
inhibitors blocking important cellular signal transduction 
pathways such as EGFR-, mTOR or Raf-signaling have 
been tested over the past years in combination with 
X-irradiation (IR) [1]. The most prominent example 
is the combination of radiotherapy with cetuximab, an 
inhibitory antibody directed against the epidermal growth 
factor receptor (EGFR) which is used to treat patients 
with head and neck squamous cell carcinoma (HNSCC; 
[2]). Many other antibodies and small molecule inhibitors 
have been tested in combination with IR in pre-clinical 
as well as clinical studies with partly promising results 
[1]. However, the main obstacle of this targeted treatment 
is the heterogeneity in respect to response, which makes 
response prediction essential. However, for effective 
prediction the molecular effects of the inhibitors on the 
irradiated cells have to be understood. 
The most critical lesions induced by X-irradiation are 
DNA lesions, especially DNA double stand breaks (DSB). 
If DNA DSB are not repaired properly, lethal chromosomal 
aberrations might occur [3]. Therefore, cancer cell-specific 
inhibition of DNA repair is one of the most wanted effects, 
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if targeted agents are combined with IR and many kinase 
inhibitors have already been shown to efficiently inhibit 
DNA DSB repair [4–9]. But still, the exact molecular 
mechanisms are usually unknown which is due to the high 
complexity of DNA damage detection and repair. 
Irradiation induces a DNA damage response (DDR). 
This DDR includes the activation of kinases such ATM, 
DNA-PKcs or ATR, leading to extensive phosphorylation 
of hundreds of proteins involved in cell cycle regulation, 
apoptosis, chromatin remodeling and especially DNA 
repair [10, 11]. Besides protein phosphorylation, additional 
posttranslational modifications such as ubiquitylation, 
SUMOylation, acetylation or PARylation and the 
recruitment of DNA proteins to the site of damage are of 
central importance [10]. Since kinase inhibitors — which 
are not primarily directed against kinases involved in the 
DDR but against those essential for signal transduction 
such as EGFR, AKT or Raf — might influence any of 
these mechanisms, differential proteomic approaches 
have to be established to analyze their influence on these 
different mechanisms in DDR and DNA repair.
So far most studies which used differential spatial 
proteomics focused on protein phosphorylation, acetylation 
or ubiquitylation after DNA damage induction only, with 
a few studies also analyzing the recruitment of repair 
proteins to the damaged DNA [10] or the re-localization 
of nuclear proteins [12, 13]. Even fewer studies have 
analyzed the influence of kinase inhibitor treatment on IR-
induced DDR and DNA repair. To address this question we 
have recently established a quantitative mass spectrometry 
(MS) approach to analyze changes in nuclear protein 
phosphorylation. Using this approach we have already 
successfully unveiled the mechanism by which EGFR 
inhibition affects DNA DSB repair in HNSCC cells, 
demonstrating the effectiveness of this approach [14]. In 
the present study, we compare this phospho-proteomic 
approach with an approach analyzing proteins, which are 
altered in their interaction with the chromatin. We used the 
HNSCC cell line UT-SCC 42B cells which were treated 
with the multi kinase inhibitor sorafenib since we have 
already reported radiosensitization and inhibition of DNA 
DSB in HNSCC cells by sorafenib [7, 15]. Following 
sorafenib treatment we detected several changes regarding 
the nuclear phospho-proteins. However, no changes 
were observed in the chromatin fraction, which indicates 
that analysis of the phospho-proteome might be more 
promising to unveil the molecular mechanism of action of 
kinase inhibitors in respect to DDR and DNA repair.
RESULTS
The aim of this study was to compare two 
quantitative MS approaches analyzing either the 
chromatin binding or the phosphorylation of nuclear 
proteins after kinase inhibitor treatment. For this purpose, 
we used the HNSCC cell lines UT-SCC 42B and the 
multi kinase inhibitor sorafenib, which has already been 
shown to inhibit DNA DSB repair and to increase the 
radiosensitivity of UT-SCC 42B cells [7].
Inhibition of DNA double strand break repair by 
sorafenib
To prove DNA repair inhibition by sorafenib in our 
experimental setting, we analyzed residual DNA DSB by 
detecting γH2AX and 53BP1 double-positive repair foci 
using immunfluorescence microsopy (Figure 1). UT-SCC 
42B cells were treated with 10 µM sorafenib for 2 h before 
irradiation with 2 Gy. The next day the cells were replated 
and stained for γH2AX/53BP1 foci 24 h later (Figure 1A). 
The quantification of four independent experiments 
revealed significantly impaired DNA DSB repair, since 
γH2AX/53BP1 foci were increased by sorafenib (Figure 1B; 
p = 0.044), which is in perfect agreement with our previously 
published data [7]. This increase was not caused by an 
elevated number of induced DSB, as demonstrated by similar 
numbers of DSB after 1 h induced by 0.5 Gy (Figure 1A). 
Labeling of cells 
To enable a quantitative analysis of changes induced 
by sorafenib we used stable isotope labeling with amino 
acids (SILAC). To this end we cultured UT-SCC 42B 
cells in the presence of either light (L) [12C6] L-arginine/
[12C6] L-lysine or heavy (H) [
13C6] L-arginine/[
13C6] 
L-lysine. Since SILAC medium contains dialyzed foetal 
bovine serum (FBS) which might reduce proliferation, we 
analyzed the proliferation of the cells by determining the 
cell number up to 10 days. As shown in Figure 2 UT-SCC 
42B cells were able to grow under SILAC conditions with 
a slightly reduced proliferation rate. 
Furthermore, incorporation of the labled aminoacids 
was complete after five passages as proven by MS analysis 
of nucelar extracts (Figure 3). Therefore for all further 
experiments cells were used which had been cultivated at 
least five passages in SILAC medium. 
Quantitative analysis of chromatin binding and 
phosphorylation of nuclear proteins by SILAC-MS
To analyze sorafenib-induced changes in the 
chromatin binding or the phosphorylation of nuclear 
proteins, two protocols were used as depicted in Figure 
4A: For both protocols the SILAC-labeled cells were 
treated with sorafenib (H) or DMSO (L) 2 h before 
irradiation with 10 Gy and harvested 30 min later. To 
determine the chromatin-bound fraction, the cells were 
trypsinized, counted and mixed in equal numbers. This 
mixture (ProbeChromatin) was lysed and the chromatin 
fraction isolated (Figure 4B) and analyzed by LC-MS/MS. 
To examine the fraction of phospho-proteins, the nuclei of 
sorafenib (H) and DMSO (L) treated cells were isolated, 
lysed and equal amounts of protein mixed (ProbePhospho). 
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The phospho-proteins were isolated (Figure 4C) and 
also analyzed by LC-MS/MS. Before the LC-MS/MS 
all samples were separated into four distinct fractions 
by SDS-PAGE to reduce complexity: fraction a) > 98 
kDa; b) 98–50 kDa; c) 50–34 kDa and d) below 34 kDa. 
Only the proteins from fractions a-c (> 98–34 kDa) were 
analyzed. To exclude changes due to SILAC cultivation, 
control pairs were prepared consisting of heavy and 
light cells which were irradiated only. These samples are 
labelled ControlChromatin and ControlPhospho (Figure 4A). 
For the ProbeChromatin 1096 peptides were identified 
with 749 peptides being also quantified (ControlChromatin: 
524 identified, 307 also quantified). For the ProbePhospho 
552 peptides were identified with 227 peptides being 
also quantified (ControlPhospho: 541 identified, 231 also 
quantified; See Supplementary Tables 1 and 2). After 
excluding albumin and keratin the peptides led to the 
identification of approximately 100 proteins in each 
sample as depicted in Table 1. On average two third of the 
identified proteins could also be quantified. 
Figure 5A shows the dot plots for all quantified 
proteins in all samples, the Control and Probe of the 
chromatin-bound (left) and the phospho-protein fraction 
(right). In order not to miss any promising proteins, we 
included also those proteins that were identified and 
quantified based on none-unique peptides (Supplementary 
Tables 3 and 4). 
In Figure 5B only those proteins were included, 
which were detected in both the Probe and the 
corresponding Control, with n indicating the number 
of proteins; 57 proteins in the chromatin fraction and 47 
in the phospho-protein fraction. Focusing on proteins 
with known functions in DNA damage detection 
and repair, 4 (chromatin fraction) and 9 (phospho-
protein fraction) proteins could be analyzed. Since 
small variations in the mixing of the samples already 
affect H/L-ratios we additionally normalized the H/L-
values by using the mean H/L-ratios of the individual 
sample (M: ControlChromatin= 1.050; ProbeChromatin= 1.093; 
ControlPhospho= 1.074; ProbePhospho= 1.009). After setting the 
thresholds for up – and downregulation at 1.5 and 0.667, 
respectively, we detected two downregulated proteins 
in the chromatin fraction and six in the phospho-protein 
fraction (Table 2). However, for both fractions two of these 
proteins were also downregulated in the Controls (brackets) 
resulting in no distinct changes in the chromatin fraction 
but four distinct downregulated proteins in the phospho-
protein fraction including the DNA repair protein NPM1.
Interestingly, the overlap of proteins detected in 
the chromatin as well as in the phospho-protein fractions 
was quite high with 40 proteins based on the Probe data 
from Figure 4A and 27 proteins based on the data from 
Figure 4B.
DISCUSSION
In this study we introduced and compared two 
differential proteomic approaches, on one hand the 
analysis of the chromatin fraction and on the other hand 
the analysis of the nuclear phospho-protein fraction of 
Figure 1: Sorafenib inhibits DSB repair in UT-SCC 42B cells. Cells were treated with sorafenib 2 h before IR and DSB repair was 
analyzed using immunofluorescence staining of γH2AX/53BP1 foci either 1 h after 0.5 Gy (DSB induction) or 24 h after 2 Gy of IR (repair). 
(A) Sample pictures of residual foci 24 h after 2 Gy (red, gH2AX; green, 53BP1; merge, yellow; DNA/DAPI, blue). (B) Quantification. 
Oncotarget4www.impactjournals.com/oncotarget
cells that had been only irradiated or also treated with 
sorafenib. Using SILAC-based MS we asked if sorafenib 
induces changes in the nuclear phospho-proteome or the 
chromatin fraction and which method might be more 
suitable for detecting kinase inhibitor-induced changes 
in a quantitative manner. These changes could serve as 
pointers for future studies to help unveil the molecular 
mechanisms underpinning DNA DSB repair inhibition 
and radiosensitization. The great advantage of this 
project is the combination of differential proteomics 
with different enrichment protocols, which allow the 
examination of clinically relevant problems. Our data 
support the notion that such functional quantitative MS 
approaches are indeed very promising tools to unveil 
the molecular effects of kinase inhibitors on DDR and 
DNA repair. Comparing both techniques, the overlap of 
Figure 2: Cell growth under SILAC conditions. Growth of UT-SCC 42B cells was determined by analyzing the cell number for 10 
days under normal (DMEM) and SILAC-conditions.
Table 1: Number of identified and quantified proteins
Chromatin-bound proteins Nuclear phospho-proteins
Number of proteins Control Probe Control Probe
Identified 100 133 104 91
Quantified 72 90 62 59
Identified / Quantified1





1Identified and quantified in the Control and the Probe.
Table 2: Regulated proteins
Chromatin-bound proteins Nuclear phospho-proteins
Protein Control Probe Control Probe
ACTB1 - - 0,8697845 0,4133276
ACTBL 0,5880827 0,6573057 0,6298223 0,4779822
ACTBM1 0,6277214 0,6463761 0,6510096 0,447166
HNRPQ1 - - 1,049211 0,554755
NPM - - 1,116355 0,4569528
ROAA - - 2,021377 0,2702799
1Quantified with none-unique peptides.
Oncotarget5www.impactjournals.com/oncotarget
Figure 3: Incorporation of amino acids labeled with stable isotopes (13C6). After five doublings in SILAC media, the 
incorporation of the stable isotopes was analyzed by MS. (A) The complete incorporation is exemplarily demonstrated by the precursor 
MS spectrum of the GVDEVTIVNILTNR(13C6) peptide from the protein Annexin A2. The intact peptide precursor-spectrum shows only 
a signal for the completely stable isotope labelled peptide ion (heavy) indicating a full incorporation of the stable isotopes. (B) Fragment-
spectrum with annotated b- and y-ion series of the stable labeled peptide GVDEVTIVNILTNR(13C6). (C–F) The precursor MS spectra 
exemplarily represent high abundant peptides (C: GGNFGFGDSR, ROA2_HUMAN; E: VLQSALAAIR, ILF2_HUMAN) and a low 
abundant peptides (D: VPPPPPIAR, HNRPC_HUMAN; F: FATHAAALSVR; SFPQ_HUMAN) with an almost 1:1 ratio for none-labeled 
(light) and stable isotope labeled (heavy) peptides. This further highlights the complete incorporation of stable isotopes and that equal 
protein amounts of none-labeled and stable isotope labeled cells were combined for differential LC-MS analysis.
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detected and quantified proteins was approximately 50%. 
However, sorafenib-induced changes were detectable 
especially in the phospho-protein fraction. This indicates 
that analyzing the nuclear phospho-proteome is more 
promising than analyzing chromatin-bound proteins. 
Besides proteins involved in gene transcription, RNA 
processing and translation we detected several proteins 
involved in replication, chromatin remodeling, DDR 
and DNA repair (see Supplementary Tables 3 and 4). 
DNA repair proteins included less prominent factors like 
ILF2, ILF3 and MATR3 but also well-known ones such 
as PARP1, Ku70 (XRCC5) and Ku80 (XRCC6). Overall, 
more DNA repair proteins were detected in the phospho-
protein fraction. This might be due to the fact, that MS 
primarily detects the most abundant proteins. Compared to 
most chemotherapeutics, IR induces only limited numbers 
of DNA lesions at equitoxic doses, and only one or a few 
of the individual DNA repair proteins are recruited to the 
site of damage [16]. Although we used a high dose of IR, 
10 Gy might still be insufficient to recruit enough DNA 
repair proteins to the DNA to be detectable. Nevertheless, 
with NPM1 we also detected a DNA repair protein, 
which was definitely regulated in the phospho-protein 
fraction after sorafenib treatment. Whether DNA repair 
inhibition by sorafenib is indeed mediated by NPM1 will 
be investigated in future studies. 
Limitations of this study are the relatively small 
amount of protein which was accessible for the analysis 
(200 µg was used for the enrichment experiment and 
approximately 60 µg were loaded on the SDS-PAGE) and 
the fact, that the Q-TOF Premier which was used generates 
only 1 precursor spectrum and 2 fragment spectra in 3s. 
Modern Orbitrap and Q-TOF instruments generate more 
than 100 fragment spectra within 3s resulting in higher 
numbers of identified peptides and proteins in recent 
studies. Furthermore, precipitation intact proteins and 
not peptides will also result in a relatively low number of 
identified proteins. But, because peptide precipitation is 
not suitable for chromatin fraction analysis, we decided 
to enrich intact proteins. Another factor which reduces 
the number proteins is the fact that we focused only on 
proteins which were quantified in both, the Control and 
Figure 4: Work flow and sample preparation. (A) Work flow. Cells were cultivated in SILAC medium containing either heavy (H) 
or light (L) amino acids. A pair of H- and L- cells were irradiated with 10 Gy (Control). Another pair of H- and L-cells was incubated for 
2 h with 10 µM sorafenib (H) or DMSO (L) before irradiation (Probe). To analyze chromatin-interacting proteins equal numbers of cells 
were mixed and the chromatin fraction was isolated. To analyze phospho-proteins the nuclei were lysed and equal amounts of proteins were 
mixed and subjected to affinity purification. The samples were separated via SDS-PAGE and lanes were cut into four fractions, proteins 
were extracted and digested by trypsin. The peptides from fractions 1–3 (> 98–34 kDa) were quantitatively analyzed using LC-MS/MS. 
(B) Western blot of cell fractionation. αCalpain served as a marker for the non-nuclear fraction, Sp1 as marker for the soluble and the 
insoluble nuclear fraction and histone H2B as marker for the insoluble chromatin fraction. (C) Western blot detecting Ku70, Ku80 and 
phosphorylated ERK in the phospho-protein eluate.
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the Probe (compare Figure 5A and 5B). However, the 
importance of such a Control in order to detect false 
positives or negatives is highlighted by the finding that in 
all MS measurements the proteins ACTBL and ACTBM 
were down-regulated in the heavy samples (see Table 2). 
This indicates a biological response to the heavy amino 
acids, which can be detected only by including an adequate 
control. In future studies the number of quantified proteins 
might be increased by including also proteins smaller than 
34 kDa, by an increased LC column length and by further 
reduction of the complexity of each sample (for example 
reduced size range of the SDS gel fractions [14] or by 
isoelectric focusing of the lysates [17]). Another way to 
increase the number of quantified proteins would be to 
decrease the cut-off of the SILACAnalyzer. However, this 
can result in a number of false-positive quantifications and 
parameters have to be optimized carefully. 
By analyzing the nuclear phospho–proteome 
using SILAC-based MS we have recently identified the 
molecular mechanism of EGFR-mediated DNA DSB 
repair inhibition in irradiated HNSCC cells [14]. In 
that study, erlotinib treatment led to multiple changes 
Figure 5: Quantitative analysis of chromatin binding and phosphorylation of nuclear proteins by SILAC-MS. (A) 
Identified and quantified proteins in the Control and Probe fractions of chromatin- bound proteins and nuclear phospho-proteins. Depicted 
is also the number of proteins (n) and the mean of the H/L ratios (M). (B) Normalized H/L ratios of all proteins detected in both the Control 
and the Probe of either the chromatin-bound or the nuclear phospho-protein fraction. The number of proteins is indicated (n) including 
the number of DNA repair-related proteins (round brackets). Thresholds for regulation were set at 1.5 (up-regulation) and 0.667 (down-
regulation). Proteins which were regulated in the Control and the Probe were bracketed.
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in the phospho-proteome but not in the composition of 
the chromatin fraction (unpublished data [18]). This 
supports our conclusion that analysis of the nuclear 
phospho-protein fraction is more promising than that of 
the chromatin fraction for the detection of interactions 
of kinase inhibitors with DDR and DNA repair. In this 
context it has to be mentioned that direct inhibition of 
DDR-related kinases by kinase inhibitors such as erlotinib 
or sorafenib cannot be excluded, but an indirect effect is 
more likely. 
In summary, we have demonstrated here, that 
differential proteomics is a worthwhile tool to investigate 
the molecular effects of kinase inhibitors on DDR and 
DNA repair. In this context, the MS-based analysis of 
the nuclear phospho-proteome might be more promising 




The HNSCC cell line UT-SCC 42B was grown in 
D-MEM (Sigma) containing 10% FBS (Biochrom) at 
37°C, 10% CO2 and 100% humidification. For SILAC 
experiments cells were cultivated in SILAC-specific 
D-MEM media containing 10% dialyzed FBS, 200 mg/l 
proline and 100 mg/l of either [12C6] L-arginine/[
12C6] 
L-lysine (light) or [13C6] L-arginine/[
13C6] L-lysine (heavy, 
Thermo Scientific). The cell number was quantified using 
a Coulter-Counter (Beckmann).
Substances
Small molecule inhibitor: sorafenib (sorafenib 
tosylate, Nexavar®, Bayer HealthCare); DMSO (vehicle, 
Sigma-Aldrich).
Irradiation
Cells were irradiated at room temperature with 200 
kV X-rays (Gulmay RS225, Gulmay Medical Ltd.: 15 mA, 
0.8 mm Be + 0.5 mm Cu filtering; dose rate of 1.2 Gy/
min).
Immunofluorescence and analysis of DNA repair
Residual γH2AX/53BP1 double positive repair 
complexes (foci) were analyzed as described earlier [8]. 
In brief, 1.5 x 105 cells were seeded onto culture slides 
(BD-Falcon), treated 24 h later and irradiated with 2 
Gy 2 h thereafter. Another 24 h later cells replated and 
were fixed, permeabilized, blocked and incubated with 
anti-γH2AX (Merck Millipore, 05–636) and anti-53BP1 
(Novus Biologicals) primary and secondary antibodies 
(Fluorescein-labeled anti-mouse: red, life technologies, 
A11005; anti-rabbit: green, GE-Healthcare, Amersham™) 
24 h later. Cell nuclei were stained with DAPI (QBiogene). 
The γH2AX/ 53BP1 foci per nucleus were analyzed 
visually by fluorescence microscopy (Zeiss Axioplan 2) 
with 630x magnification. At least 100 intact nuclei were 
randomly chosen for the evaluation. Experiments were 
repeated four times.
Isolation of chromatin-bound proteins
The Subcellular Protein Fractionation Kit 
(Thermo Scientific) was used according to the producer´s 
instruction. In brief, trypsinized cells were centrifuged 
(5 min, 500 g, 4°C) and 2 × 106 cells were incubated with 
100 µl CEB buffer and gently mixed for 10 min on a 
rotator at 4°C. All buffers contained phosphatase/protease 
inhibitors (Halt inhibitor cocktail, Thermo Scientific). 
After centrifugation (5 min, 500 g, 4°C) the supernatant 
was collected (cytoplasmic proteins). The cell pellet was 
consecutively incubated with 100 µl MEB (membrane-
bound proteins), 50 µl NEB (soluble nuclear proteins) and 
50 µl NEB with 5 µl CaCl2 (100 mM) and 3 µl MNnase 
(300 U) (chromatin-bound proteins) with respective 
centrifugation.
Isolation of phospho-proteins
Plateau phase cells were harvested mechanically, 
resuspended in PBS and centrifuged (5 min, 1000 g, 
4°C). The cell pellet was resuspended in 500 µl hypotonic 
lysis-buffer (10 mM HEPES pH 7.9, 10 mM KCL, 0.1 
mM EDTA, 0.1 mM EGTA, phosphatase/protease 
inhibitors (Halt inhibitor cocktail, Thermo Scientific)) 
and incubated for 15 min on ice. NP-40 was added to a 
final concentration of 0.625%, the sample mixed for 10 
s and centrifuged for 10 min (1000 g, 4°C). The pellet 
containing the nuclei (supernatant, cytoplasmic fraction) 
was resuspended in 500 µl Extraction/ Loading Buffer 
(Clontech), incubated on ice for 20 min and mixed 
periodically. After centrifugation (20 min, 20,000 g, 
4°C) the supernatant (nuclear fraction) was treated with 
ultrasound for 10 s and used for phospho-protein isolation, 
which was performed using the TALON®PMAC Magnetic 
Phospho Enrichment Kit (Clontech) according to the 
producer´s instruction. In brief, 200 µg nuclear protein 
lysates were incubated with 200 µl magnetic beads and 10 
mM NaF for 1 h at 4°C while gently mixing on a rotator. 
The supernatant was collected. After washing the beads 
three times the phosphorylated proteins were eluted with 
50 µl elution buffer.
Protein quantification 
Nuclear protein concentration was quantified using 




Proteins were detected by Western blot according 
to the standard protocol. Primary antibodies from Cell 
Signaling Technology: anti-Ku70 (rabbit, #4104), anti-
Ku80 (rabbit, #2753), anti-pERK1/2 (Thr202/Tyr204, 
rabbit, #4370); from Merck Millipore: anti-calpain 
(mouse, 208730); from Santa Cruz Biotechnology: 
anti-SP1 (rabbit, sc14027) and from Imgenex: anti-
H2B (rabbit, #IMG-359). Secondary antibodies from 
Amersham: anti-rabbit and anti-mouse HRP-conjugated. 
Signals were determined by chemiluminescence using the 
ECL™ Western Blotting Detection Reagents (Amersham).
LC-MS/MS analysis
Proteins were separated via SDS-PAGE using a 15% 
Bis-Tris. The gels were stained with Coomassie blue for 
30 min followed by destaining. Each lane was separated 
into four fractions (a => 98 kDa; b = 98–50 kDa; c = 50–
34 kDa and d = < 34 kDa). For fraction a-c a tryptic in-
gel digestion was performed in accordance to Shevchenko 
et al. [19]. After digestion, the samples were evaporated 
and mass spectrometric proteome analysis was performed 
by injecting the samples on a nano-ultra pressure liquid 
chromatography system (nano-UPLC; nanoACQUITY, 
Waters, Manchester, UK) coupled via electrospray-
ionization (ESI) to a quadrupole time-of-flight (QTOF) 
mass spectrometer (QTOF Premier, Micromass/Waters, 
Manchester, UK) as described by Kwiatkowski et al. 
[20] with slight modifications. After sample loading on a 
trapping column (nanoAcquity UPLC PST trap column, 
C18, 180 μm × 20 mm, 5 µm, 100 Ǻ, Waters, Manchester, 
UK; buffer A: 0.1% FA in HPLC-H2O; buffer B: 0.1% 
FA in ACN), peptides were eluted onto the separation 
column (nanoAcquity UPLC BEH column, C18, 75 μm 
× 150 mm, 100 Ǻ Waters, Manchester, UK; 200 nL/min, 
gradient: 2−35% B in 30 min). The spray was generated 
from a fused-silica emitter (I.D. 10 μm, New Objective, 
Woburn, USA) at a capillary voltage of 1650 V, a source 
temperature of 100°C and a cone voltage of 40 V in 
positive ion mode. For MS/MS measurements, data were 
recorded in the data dependent acquisition mode (DDA). 
MS survey scans were performed over an m/z range from 
400–1300 with a scan-time of 0.6 s and an interscan 
delay of 0.05 s. The two most abundant signals were used 
for fragmentation. MS/MS spectra were obtained from 
100–1500 m/z with a scan-time of 0.95 s and a collision 
ramp from 22–30 eV. An online exclusion was used to 
prevent multiple fragmentation events (exclusion time: 
20 s, exclusion window: +/− 2 m/z).
Data analysis of LC-MS/MS data
Data analysis was performed as described earlier 
[14, 17] with slight modifications. Briefly, data from 
LC-MS/MS analysis were analyzed using the open-source 
software framework OpenMS [21] and the OpenMS 
Proteomic Pipeline (TOPPAS) [22]. For peptide and 
protein identification, mzML-files were searched against 
a human decoy-database (Swiss-Prot, www.uniprot.
org, 20,161 entries) using two different search engines 
(open mass spectrometry search algorithm (OMSSA) 
[23] XTANDEM [24]). The search was performed with a 
precursor mass tolerance of 35 ppm and a fragment mass 
tolerance of 0.1 Da. Carbamidomethylation on cystein 
residues was considered as a fixed modification. An 
oxidation of methionine residues as well as a 13C6-label on 
arginine and lysine residues were considered as variable 
modifications. Peptides were identified with a q-value of 
0.05. For SILAC quantification the raw data files were 
converted to *.mzXML in profile mode using massWolf 
file converter. Further data processing was carried out 
with TOPPAS. The *.mzXML files were converted to 
*.mzML. For subsequent data processing the mzML files 
were filtered (only MS1 level, rt-range [s]: 600–2400) 
and smoothed (savitsky golay algorithm, frame length: 
13, polynomial order: 4). SILAC pairs were detected 
and quantified using SILACAnalyzer with the following 
parameters: one missed cleavage, retention time threshold 
10 s, intensity cutoff 20 counts, intensity correlation 0.7 
and a model deviation of 1.8. A peptide required at least 
three isotopic peaks and maximal seven isotopic peaks to 
be taken into account by the SILACAnalyzer. Detected 
SILAC pairs were exported as *.consensusXML and 
matched with peptide identifications (*idXML) using 
IDMapper (retention time tolerance: 10 s, m/z-tolerance: 
1 Da). Results were exported as *.csv and further statistical 
processing was carried out using mathematica. 
Data evaluation 
Microsoft Excel and Prism 5 software (GraphPad 
Software) software were used for analyzing and graphing 
the data. Except for the mass spec experiments, the data 
were repeated at least three times and are presented as 
mean values (+/-SEM). The Prism 5 software was used for 
analyzing and graphing the data. The paired student’s t-test 
was performed for the statistical analysis. P-values were 
calculated using two-sided tests (*p < 0.05; **p < 0.01; ***p 
< 0.001).
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